X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5) 5
oncology (5) 5
female (4) 4
humans (4) 4
male (4) 4
middle aged (4) 4
stem-cell transplantation (4) 4
adult (3) 3
cancer (3) 3
chemotherapy (3) 3
leukemia, myeloid, acute - drug therapy (3) 3
leukemia, myeloid, acute - mortality (3) 3
transplants & implants (3) 3
abridged index medicus (2) 2
adolescent (2) 2
age factors (2) 2
aged (2) 2
aged, 80 and over (2) 2
antineoplastic combined chemotherapy protocols - therapeutic use (2) 2
bone marrow (2) 2
clinical trials (2) 2
consolidation (2) 2
cytarabine - therapeutic use (2) 2
elderly-patients (2) 2
germany (2) 2
hematology (2) 2
hematology, oncology and palliative medicine (2) 2
hematopoietic stem cell transplantation (2) 2
internal medicine (2) 2
leukemia, myeloid, acute - therapy (2) 2
medicine, general & internal (2) 2
mortality (2) 2
patient outcomes (2) 2
prognosis (2) 2
risk factors (2) 2
studies (2) 2
therapy (2) 2
time factors (2) 2
treatment outcome (2) 2
1st remission (1) 1
acute myelogenous leukemia (1) 1
acute myeloid-leukemia (1) 1
aml (1) 1
analysis (1) 1
antibiotics, antineoplastic - therapeutic use (1) 1
antigens, cd34 - blood (1) 1
antimetabolites, antineoplastic - therapeutic use (1) 1
antimitotic agents (1) 1
antineoplastic agents (1) 1
antineoplastic combined chemotherapy protocols - adverse effects (1) 1
bavaria civilization (1) 1
bavaria intellectual life (1) 1
blood cell count (1) 1
blood platelets (1) 1
blood transfusion (1) 1
bone-marrow (1) 1
bone-marrow-transplantation (1) 1
care and treatment (1) 1
cells (1) 1
chemotherapy, adjuvant (1) 1
chromosome aberrations (1) 1
civilization (1) 1
classification (1) 1
combination (1) 1
comparative analysis (1) 1
complex karyotype (1) 1
conferences (1) 1
cytarabine (1) 1
cytarabine - administration & dosage (1) 1
daunorubicin - administration & dosage (1) 1
daunorubicin - therapeutic use (1) 1
decitabine (1) 1
disease progression (1) 1
disease-free survival (1) 1
dose cytarabine (1) 1
double-blind method (1) 1
elderly patients (1) 1
enlightenment (1) 1
favorable prognosis (1) 1
flt3 mutations (1) 1
fms-like tyrosine kinase 3 - genetics (1) 1
health aspects (1) 1
hematologic neoplasms - blood (1) 1
hematologic neoplasms - complications (1) 1
hematologic neoplasms - therapy (1) 1
hematopoietic stem cell transplantation - methods (1) 1
hemorrhage - etiology (1) 1
hemorrhage - prevention & control (1) 1
high-dose cytarabine (1) 1
hypertension (1) 1
hypomethylating agents (1) 1
induction chemotherapy (1) 1
intellectual life (1) 1
internet (1) 1
kaplan-meier estimate (1) 1
karyotype (1) 1
leukemia (1) 1
leukemia, myeloid, acute - diagnosis (1) 1
medical prognosis (1) 1
medicine & public health (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 16, pp. 1691 - 1699
Summary Background Preclinical data and results from non-randomised trials suggest that the multikinase inhibitor sorafenib might be an effective drug for the... 
Hematology, Oncology and Palliative Medicine | AML | ONCOLOGY | ACUTE MYELOGENOUS LEUKEMIA | BONE-MARROW | CLASSIFICATION | FLT3 MUTATIONS | CYTARABINE | STEM-CELL TRANSPLANTATION | COMBINATION | ELDERLY-PATIENTS | CHEMOTHERAPY | Niacinamide - analogs & derivatives | Recurrence | Age Factors | Cytarabine - therapeutic use | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Protein Kinase Inhibitors - adverse effects | Transplantation, Homologous | Neoadjuvant Therapy - mortality | Time Factors | Phenylurea Compounds - adverse effects | Leukemia, Myeloid, Acute - drug therapy | Adult | Female | Chemotherapy, Adjuvant | Daunorubicin - therapeutic use | Double-Blind Method | Risk Factors | Kaplan-Meier Estimate | Niacinamide - adverse effects | Proportional Hazards Models | Hematopoietic Stem Cell Transplantation | Niacinamide - therapeutic use | Phenylurea Compounds - therapeutic use | Treatment Outcome | Disease Progression | Leukemia, Myeloid, Acute - mortality | Disease-Free Survival | Antimetabolites, Antineoplastic - therapeutic use | Leukemia, Myeloid, Acute - diagnosis | Antibiotics, Antineoplastic - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Neoadjuvant Therapy - adverse effects | Protein Kinase Inhibitors - therapeutic use | Germany | Antimitotic agents | Clinical trials | Chemotherapy | Antineoplastic agents | Standards | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 380, Issue 9850, pp. 1309 - 1316
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9757, pp. 2000 - 2008
Journal Article
Im Focus Onkologie, ISSN 1435-7402, 9/2015, Volume 18, Issue 9, pp. 20 - 21
Lohnt der routinemäßige Einsatz Mikroarray-basierter Genomtests bei der akuten myeloischen Leukämie (AML)? Um die Prognose besser abschätzen zu können,... 
Oncology | Medicine & Public Health | Hematology | Surgical Oncology
Journal Article
2001, Schriftenreihe zur bayerischen Landesgeschichte, ISBN 9783406107177, Volume Bd. 136, xxxvi, 473
Book
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.